Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record.

Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

Chang, S M, Kuhn, J G, Rizzo, J, Robins, H I, Schold, S C, Spence, A M, Berger, M S, Mehta, M P, Bozik, M E, Pollack, I, Gilbert, M, Fulton, D, Rankin, C, Malec, M, Prados, M D·1998·Journal of Clinical Oncology

Abstract

PURPOSE: To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. PATIENTS AND METHODS: Patients were stratified by starting dose of paclitaxel and concurrent anticonvulsant (AC) use and were treated in cohorts of three patients. The starting dose was 240 mg/m2 administered intravenously with escalations of 30 mg/m2 until the MTD was established. Pharmacokinetic data were obtained for each patient for the first infusion. Tumor response was assessed at 6-week intervals and treatment was continued until documented tumor progression, unacceptable toxicity, or a total of 12 paclitaxel infusions. RESULTS: From April 1995 to December 1996, 34 patients were treated; 27 patients in the AC group and seven patients in the non-AC group. The MTD for patients who received ACs was established at 360 mg/m2 and the dose-limiting toxicity (DLT) was central neurotoxicity, characterized as transient encephalopathy and seizures. In contrast, the MTD for patients who did not receive ACs was 240 mg/m2, and myelosuppression, gastrointestinal toxicity, and fatigue were the DLTs. Pharmacokinetic data confirmed that the plasma drug levels and clearance rates were similar for patients in both groups at the respective dose levels that produced DLTs. CONCLUSION: The pharmacokinetics of paclitaxel are altered by ACs, and significantly larger doses of the drug can be administered to patients with brain tumors on AC therapy. The toxicity profile is different for patients on AC therapy treated at these higher doses. A phase II study has been initiated that uses a dose of 330 mg/m2 for patients on AC therapy and 210 mg/m2 for patients not on AC therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1998.16.6.2188

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 166

Metadata

Authors
Chang, S. M., Kuhn, J. G., Rizzo, J., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., Gilbert, M., Fulton, D., Rankin, C., Malec, M., & Prados, M. D.
Venue
Journal of Clinical Oncology
Published
1998-06
Volume
16
Issue
6
Pages
2188-2194
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2080969227
Cited by
166
References
0
FWCI
7.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. https://app.cochat.ai/papers/10.1200/jco.1998.16.6.2188
The paper
Chang, S. M., Kuhn, J. G., Rizzo, J., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., Gilbert, M., Fulton, D., Rankin, C., Malec, M., & Prados, M. D. (1998). Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.6.2188

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.